Cancer Pain Clinical Trial
Official title:
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group Phase 3 study in cancer subjects requiring treatment with background opioids for pain due to bone metastasis. Approximately 144 subjects will be randomized to one of 2 treatment groups in a 1:1 ratio (approximately 72 subjects per group). Subjects will receive a total of 3 subcutaneous injections, separated by 8 weeks in addition to background opioids administered throughout the study. Treatment groups will include: 1. Placebo SC (matching tanezumab SC) in addition to background opioid therapy. 2. Tanezumab 20 mg SC in addition to background opioid therapy. The study consists of three periods: Pre-Treatment (up to 37 days), Double-Blind Treatment (24 weeks) and Safety Follow-up (24 weeks). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
| Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
| Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
| Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
| Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
| Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
| Active, not recruiting |
NCT04095234 -
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
|
Phase 2 | |
| Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
| Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
| Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
| Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
| Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
| Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
| Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
| Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
| Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A | |
| Completed |
NCT02660229 -
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
|
Phase 4 |